News & Updates

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

15 Apr 2025 by

Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

15 Apr 2025

Oral semaglutide reduces CV risk in T2D patients

15 Apr 2025 by

Once-daily treatment with oral semaglutide, a GLP-1* receptor agonist, significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD), according to the SOUL** trial presented at ACC.25.

Oral semaglutide reduces CV risk in T2D patients

15 Apr 2025

Is it advisable to resume DOAC use 1 day after colorectal ESD?

14 Apr 2025 by

Resumption of direct oral anticoagulants (DOACs) a day after undergoing colorectal endoscopic submucosal dissection (ESD) results in fewer thromboembolic events without elevating the risk of delayed bleeding compared with 2 or 3 days after ESD, reports a study.

Is it advisable to resume DOAC use 1 day after colorectal ESD?

14 Apr 2025

Stepwise DAPT de-escalation on par with standard therapy in ACS

13 Apr 2025 by

A stepwise dual antiplatelet therapy (DAPT) de-escalation strategy among patients with acute coronary syndrome (ACS) who could be treated by paclitaxel-coated balloons without stents demonstrates noninferiority to the standard 12-month DAPT for all net adverse clinical events, according to a study.

Stepwise DAPT de-escalation on par with standard therapy in ACS

13 Apr 2025

Medications for ADHD linked to blood pressure, pulse elevation

12 Apr 2025

Exposure to pharmacological treatments for attention-deficit hyperactivity disorder (ADHD) appears to confer increases in blood pressure and pulse among children, teens, and adults, according to the results of a meta-analysis.

Medications for ADHD linked to blood pressure, pulse elevation

12 Apr 2025

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

11 Apr 2025 by

In the long-term maintenance period after percutaneous coronary intervention (PCI), monotherapy with clopidogrel appears to work better than aspirin at preventing major adverse cardiac and cerebrovascular events in Asian patients at high risk of recurrent ischaemic events, as shown in the open-label SMART-CHOICE 3 trial conducted in South Korea.

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

11 Apr 2025

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

10 Apr 2025 by

Elderly patients with aortic stenosis who received dapagliflozin after transcatheter aortic-valve implantation (TAVI) had better outcomes than those who did not receive the drug, according to the DapaTAVI* trial presented at ACC.25.

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

10 Apr 2025

Original New Drug Application Approvals by US FDA (16-31 March 2025)

10 Apr 2025

New drug applications approved by US FDA as of 16-31 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2025)

10 Apr 2025

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

09 Apr 2025

Women are more likely than men to fill prescriptions for statin, particularly high-intensity dosages, after undergoing coronary artery bypass surgery (CABG), with statin therapy equally effective at reducing mortality for both sexes, according to a study.

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

09 Apr 2025

Heart failure precedes rapid, sustained cognitive decline

08 Apr 2025 by

A rapid and persistent deterioration in cognitive function appears to occur following the onset of heart failure (HF), as reported in a study.

Heart failure precedes rapid, sustained cognitive decline

08 Apr 2025

News & Updates

Filter by Specialty:

Specialty:

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?

Oral semaglutide reduces CV risk in T2D patients

Oral semaglutide reduces CV risk in T2D patients

Is it advisable to resume DOAC use 1 day after colorectal ESD?

Is it advisable to resume DOAC use 1 day after colorectal ESD?

Stepwise DAPT de-escalation on par with standard therapy in ACS

Stepwise DAPT de-escalation on par with standard therapy in ACS

Medications for ADHD linked to blood pressure, pulse elevation

Medications for ADHD linked to blood pressure, pulse elevation

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

Original New Drug Application Approvals by US FDA (16-31 March 2025)

Original New Drug Application Approvals by US FDA (16-31 March 2025)

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

Heart failure precedes rapid, sustained cognitive decline

Heart failure precedes rapid, sustained cognitive decline